<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Trubion Cuts One-Fourth of Workforce</title>
	<atom:link href="http://www.xconomy.com/seattle/2009/02/25/trubion-cuts-one-fourth-of-workforce/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/seattle/2009/02/25/trubion-cuts-one-fourth-of-workforce/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 11 Feb 2012 01:49:51 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.4</generator>
	<item>
		<title>By: New developments in chronic lymphocytic leukemia (CLL) &#124; Pharma Strategy Blog</title>
		<link>http://www.xconomy.com/seattle/2009/02/25/trubion-cuts-one-fourth-of-workforce/comment-page-1/#comment-239528</link>
		<dc:creator>New developments in chronic lymphocytic leukemia (CLL) &#124; Pharma Strategy Blog</dc:creator>
		<pubDate>Sun, 24 Oct 2010 17:46:14 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=13977#comment-239528</guid>
		<description>[...] (Gemin X Biotechnologies), polyphenon E (Polyphenon), PRO-131921 (Genentech), SPC-2996 (Santaris), TRU-016 (Trubion) and motexafin gadolinium [...]</description>
		<content:encoded><![CDATA[<p>[...] (Gemin X Biotechnologies), polyphenon E (Polyphenon), PRO-131921 (Genentech), SPC-2996 (Santaris), TRU-016 (Trubion) and motexafin gadolinium [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>

